Fusion Antibodies plc (LON:FAB – Get Free Report) shares fell 38.5% during trading on Thursday. The stock traded as low as GBX 4.70 and last traded at GBX 6. Approximately 7,380,445 shares traded hands during mid-day trading, an increase of 1,568% from the average session volume of 442,459 shares. The stock had previously closed at GBX 9.75.
Fusion Antibodies Stock Performance
The company has a debt-to-equity ratio of 20.41, a quick ratio of 2.36 and a current ratio of 2.82. The business has a 50 day moving average price of GBX 10.81 and a two-hundred day moving average price of GBX 11.78. The company has a market cap of £8.26 million, a P/E ratio of -6.60 and a beta of 1.24.
Fusion Antibodies (LON:FAB – Get Free Report) last issued its earnings results on Monday, September 14th. The company reported GBX (1.20) earnings per share for the quarter. Fusion Antibodies had a negative net margin of 54.45% and a negative return on equity of 97.87%. On average, sell-side analysts anticipate that Fusion Antibodies plc will post -130.00 earnings per share for the current year.
Fusion Antibodies Company Profile
Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.
Further Reading
- Five stocks we like better than Fusion Antibodies
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Fusion Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fusion Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.
